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The mechanisms responsible for effective vs. ineffective viral containment are central to immunoprevention and therapies of retroviral
infections. Feline leukemia virus (FeLV) infection is unique as a naturally occurring, diametric example of effective vs. ineffective retroviral
containment by the host. We developed a sensitive quantitative real-time DNA PCR assay specific for exogenous FeLV to further explore the
FeLV–host relationship. By assaying p27 capsid antigen in blood and FeLV DNA in blood and tissues of successfully vaccinated,
unsuccessfully vaccinated, and unvaccinated pathogen-free cats, we defined four statistically separable classes of FeLV infection,
provisionally designated as abortive, regressive, latent, and progressive. These host–virus relationships were established by 8 weeks post-
challenge and could be maintained for years. Real-time PCR methods offer promise in gaining deeper insight into the mechanisms of FeLV
infection and immunity.
D 2004 Elsevier Inc. All rights reserved.
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Feline leukemia virus (FeLV) is a naturally occurring,
contagiously transmitted, gammaretrovirus of cats (Hardy et
al., 1973; Hoover et al., 1972; Jarrett et al., 1964; Kawakami
et al., 1967; Rickard et al., 1969). Its pathogenic effects are
paradoxical, causing both cytoproliferative (e.g., lymphoma
or myeloproliferative disorder) and cytosuppressive (e.g.,
immunodeficiency or myelosuppression) disease (Anderson
et al., 1971; Cockerell and Hoover, 1977; Cockerell et al.,
1976; Hoover et al., 1974; Jarrett et al., 1964; Kawakami
et al., 1967; Mackey et al., 1975; Perryman et al., 1972;
Rickard et al., 1969). While many FeLV-exposed cats
(estimated at ~30%) develop progressive infection and
FeLV-related disease, at least twice as many (estimated at
~60%) develop regressive infection marked by an effective
and durable immune response that contains and possibly
extinguishes viral replication, thereby abrogating develop-0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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1991; Hoover et al., 1981; Rojko et al., 1979). That effective
host containment of FeLV infection can occur prompted
research leading to development of the first vaccine for a
naturally occurring retroviral infection (Hoover et al., 1991;
Lewis et al., 1981; Sparkes, 1997).
Available evidence suggests that the interplay between
the host and virus within the first 4 weeks after FeLV
exposure results in either (a) failure of host immune
response to contain viral replication in lymph nodes,
epithelia, and bone marrow precursor cells or (b) successful
host immune response resulting in curtailment of viral
replication (Hoover and Mullins, 1991; Hoover et al., 1981;
Rojko et al., 1979). Cats with progressive infection develop
persistent antigenemia as detected by p27 capsid antigen
capture in blood and have neither virus neutralizing
antibodies (VN Ab) nor high levels of FeLV-specific
cytotoxic lymphocytes (CTLs) (Flynn et al., 2000, 2002;
Hoover and Mullins, 1991). By contrast, cats with
regressive infection do not develop persistent antigenemia
but do produce VN Ab and a detectable CTL response05) 272–283
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Because identification of FeLV infection has necessarily
been based on assays that rely on viral replication and
substantial viremia/antigenemia, it is unclear whether
regressors retain latent (nonproductive) infection or instead
may eliminate all cells bearing integrated FeLV provirus.
Several laboratories have shown that it is possible to
reactivate FeLV from some cats with regressive infection
(Madewell and Jarrett, 1983; Post and Warren, 1980; Rojko
et al., 1982). Despite this, attempts by other laboratories to
amplify viral DNA sequences in circulating and/or bone
marrow cells from cats with suspected latent infections
have been unsuccessful using conventional PCR (Herring
et al., 2001; Jackson et al., 1996; Miyazawa and Jarrett,
1997). Similar to FeLV regressors, protected vaccinates do
not develop persistent antigenemia. To the authors knowl-
edge, however, studies assessing vaccinates for potential
latent infections using PCR have not been performed
(Sparkes, 1997).
Recent studies employing quantitative real-time PCR in
experimental FeLV infections have shown that the early
circulating proviral burden influences the course of infec-
tion and that real-time PCR detected provirus in circulating
cells from cats with undetectable or transient antigenemia
(Flynn et al., 2002; Hofmann-Lehmann et al., 2001). To
explore further the FeLV–host relationship and assess the
presence of latent viral DNA in circulation and tissue, we
developed a quantitative real-time PCR assay and examined
the early (weeks post-challenge) and late (years post-
challenge) phases of experimental FeLV infection in both
unvaccinated animals and those primed by vaccination.
Here we examine proviral and p27 levels in FeLV-61E-A-
challenged cats given effective, ineffective, or no FeLV
vaccine. Based on the results of these studies, we suggest
four categories within the spectrum of FeLV infection,
which we have provisionally designated as abortive,
regressive, latent, and progressive.Table 1
Real-time DNA PCR vs. p27 capsid capture ELISA for FeLV detection
Real-time PCR Total
(+) ()
p27 ELISA (+) 76 0 76
() 24 23 47
Total 100 23 123
Kappa value = 0.53 (fair agreement).Results
Validation of FeLV quantitative real-time PCR
Specificity
The analytical specificity of the FeLV quantitative real-
time PCR assay was confirmed by sequencing two
amplicons after agarose gel confirmation (data not shown).
Using BLAST (Altschul et al., 1990; Wheeler et al., 2003),
the amplicon sequences were shown to be identical to that of
FeLV-61E-A (data not shown). Peripheral blood mononu-
clear cells (PBMC) and lymphoid tissues from FeLV-naRve,
specific-pathogen-free (SPF) cats were consistently negative
for FeLV DNA (49/49 samples from 18 cats; data not
shown); thus, endogenous FeLV sequences were not
amplified. Consequently, diagnostic specificity was 100%
in FeLV-61E-A-infected animals.Sensitivity
The analytical sensitivity of the FeLV real-time PCR
assay was assessed in end-point dilution experiments. These
studies consistently detected five copies of the p61E-FeLV
plasmid standard (data not shown). The template control (no
DNA, PCR-grade H2O only), negative control (FeLV-naRve,
SPF cat DNA), and samples containing 0.5 copy of the
plasmid standard never crossed threshold. All FeLV-61E-A-
infected cats that tested positive for p27 capsid antigen also
were positive by real-time PCR (76/76 samples from 23
cats) (Table 1). Thus, diagnostic sensitivity in the animals
studied was 100%.
Linearity
The linear range of the plasmid standard curve was
evaluated. Amplification of 10-fold serial dilutions starting
at 5  108 copies and ending at 5  100 copies of the p61E-
FeLV plasmid standard from 18 independent experiments
demonstrated linearity over 8 orders of magnitude, gener-
ated a standard curve correlation coefficient of 0.999, and
produced an amplification efficiency (Klein et al., 2001) of
96.6% (data not shown).
Amplification efficiency
The amplification efficiencies of FeLV-61E-A-infected
cat DNA and the p61E-FeLV plasmid standard were
compared to validate quantification using the plasmid
standard. Equivalent amplification efficiencies are indicated
by regression line slopes (s) with less than 0.1 difference
(Ds) (Gut et al., 1999). The observed amplification
efficiencies of the target DNA (s = 3.32, R2 = 0.997) vs.
the plasmid standard (s = 3.30, R2 = 0.999) had a Ds = 0.02
(data not shown). Thus, quantification using the plasmid
standard was expected to be valid.
Reproducibility
The within-run and between-run precision of the FeLV
real-time PCR assay was evaluated. Several dilutions of
the p61E-FeLV plasmid standard and of FeLV-61E-A-
infected cat DNA were amplified 10 times within the
same reaction plate and between 10 different reaction
plates. The threshold cycle coefficients of variation,
CV(CT), for the within-run precision was 0.31–1.11%
and the CV(CT) for the between-run precision was 0.56–
1.16% (data not shown). Thus, the assay was considered
highly reproducible.
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FeLV-challenged animals
Sera and PBMC collected pre-challenge and every 2
weeks thereafter through 8 weeks post-challenge (PC) were
analyzed for FeLV p27 capsid antigen via capture ELISA
and for FeLV U3 LTR DNA via quantitative real-time
PCR. None of the cats had detectable antigen or viral DNA
pre-challenge.
Animals receiving Vaccine A
FeLV p27 was never detected in 9 of the 10 cats (90%),
which received Vaccine A (Fig. 1A). Of these nine protected
vaccinates, four never had detectable viral DNA, two
developed transient low provirus loads (median: 130
copies/106 PBMC; range: 0 to 1723 copies/106 PBMC),
which gave way to undetectable levels (1 cat by 6 weeks
and 1 cat by 8 weeks), and three had persistent low viral
DNA levels (median: 225 copies/106 PBMC; range: 0 to
7744 copies/106 PBMC) (Fig. 1B). In the one persistently
antigenemic failed vaccinate, a persistent high proviral
burden was present PC (median: 477,999 copies/106
PBMC; range: 17,140 to 578,572 copies/106 PBMC).
Animals receiving Vaccine B
Thirteen of the 15 cats (86%) given Vaccine B developed
persistent antigenemia and persistent high proviral burdens
PC (median: 259,013 copies/106 PBMC; range: 7330 to
2,224,869 copies/106 PBMC). p27 was never detected in the
remaining two vaccinates. In one of these latter animals,
viral DNA also was never detected whereas in the second
animal, persistent low proviral load (median: 18,790 copies/
106 PBMC; range: 6079 to 30,854 copies/106 PBMC) was
present.
Unvaccinated controls
Seven of the 10 unvaccinated control cats (70%)
developed persistent antigenemia and high proviral bur-
dens PC (median: 265,572 copies/106 PBMC; range:
11,942 to 1,508,006 copies/106 PBMC). The remaining
three animals experienced transient antigenemia between 2
and 6 weeks PC, after which p27 was no longer detectable
(1 cat by 4 weeks and 2 cats by 6 weeks). These latter cats
retained persistent moderate proviral burdens (median:
40,969 copies/106 PBMC; range: 860–328,249 copies/106
PBMC).
Using repeated measures-ANOVA and the Tukey–
Kramer post hoc test, statistically significant differences
(P b 0.01) in p27 and viral DNA levels were present
between Vaccine A vs. Vaccine B and between Vaccine A
vs. unvaccinated Controls. Results for Vaccine B were not
statistically different from the unvaccinated Controls.PF ¼ Incidence of Persistent Antigenemia in Controls In
Incidence of Persistent AnPreventable fraction
The preventable fraction (PF) is used to express vaccine
efficacy due to the inherent resistance of approximately 60%
of unvaccinated cats to development of persistent antigene-
mia after FeLV challenge (Pollack and Scarlett, 1990), as
shown in Eq. (1). The PF for Vaccine Awas 85.7%. The PF
for Vaccine B was 23.8%.
Host–virus relationships defined using circulating p27 and
viral DNA levels
In the original FeLV–host relationship classification
scheme, FeLV-exposed animals that did not develop
persistent antigenemia were identified as having experi-
enced regressive infections. The results of the present study
suggest that FeLV-exposed antigen-negative cats represent a
spectrum of host–virus relationships.
The five FeLV-61E-A-inoculated cats in which neither
p27 nor viral DNAwere detected at any time were classified
as having experienced abortive infection (Table 2; Fig. 2).
Four of these cats were vaccinated with Vaccine A and 1
with Vaccine B.
The six cats that never developed detectable antigenemia
but in which transient or low persistent circulating viral
DNA levels were detectable (median: 225 copies/106
PBMC; range: 0–30,854 copies/106 PBMC) were classified
as having experienced regressive infection. Five of these
cats were vaccinated with Vaccine A and 1 with Vaccine B.
An initial low proviral burden detected at 4 weeks PC was
no longer demonstrable by 8 weeks PC in two cats
vaccinated with Vaccine A.
Transient antigenemia was demonstrated in three unvac-
cinated control cats that retained persistent moderate
proviral loads in blood (median: 40,969 copies/106 PBMC;
range: 860–328,249 copies/106 PBMC). These animals
were classified as retaining latent infection.
Finally, 21 cats developed persistent antigenemia with
concurrent persistent high circulating proviral burdens
(median: 269,328 copies/106 PBMC; range: 7330–
2,224,869 copies/106 PBMC). These animals, as in previous
classification schemes, were designated as progressive
infection.
Using repeated measures-ANOVA and the Tukey–
Kramer post hoc test, statistically significant differences
( P b 0.01) in p27 values were identified between
progressive vs. abortive, progressive vs. regressive, and
progressive vs. latent infection. Statistically significant
differences (P b 0.01) in viral DNA burdens were present
among all FeLV categories (with the exception of latent vs.
progressive infection): abortive vs. regressive, abortive vs.
latent, abortive vs. progressive, regressive vs. latent, and
regressive vs. progressive infection.cidence of Persistent Antigenemia in Vaccinates
tigenemia in Controls
ð1Þ
Fig. 1. Vaccine A (Fort Dodge Fel-O-Vax Lv-K) protected cats against FeLV challenge: 9 of 10 vaccinated cats did not develop detectable antigenemia and had
low to undetectable proviral burden. Sera and PBMC collected at challenge and every 2 weeks thereafter through 8 weeks PC were analyzed for FeLV p27
capsid antigen via capture ELISA (A) and for FeLV DNA via quantitative real-time PCR (B). Only 1 of 10 Vaccine A cats developed persistent antigenemia
with persistent high proviral burden. By contrast, 13 of 15 Vaccine B cats and 7 of 10 unvaccinated control cats developed persistent antigenemia and high
proviral burdens. Statistically significant differences ( P b 0.01) for both p27 and viral DNA levels were detected between Vaccine A vs. Vaccine B and Vaccine
A vs. unvaccinated Controls. Results for Vaccine B were not statistically different from the unvaccinated Controls. Graphed boxplots show the 10th, 25th, 50th
(median), 75th, and 90th percentiles of a variable. Values above the 90th and below the 10th percentile are not shown. (A) The dotted line represents the
threshold for positive results (z10% of the positive control).
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detection
The kappa statistic was calculated to assess the level of
agreement, beyond that which might be expected due to
chance, between the p27 capture ELISA and the real-time
PCR assay (Table 1). All samples that tested positive for p27Table 2
Putative categories for FeLV–host relationships in vaccinated and unvaccinated c
Group Response category
Abortive Regressive
Provirus () Provirus (+)a
Antigen () Antigen ()
Vaccine A 4 5
Vaccine B 1 1
Control 0 0
Total 5 6
a After detecting an initial low proviral load, two of the six cats with regressive inf
received Vaccine A.capsid antigen were positive by real-time PCR (76 samples
from 23 cats). All samples with undetectable viral DNA
(real-time PCR negative) had undetectable antigen (ELISA
negative) (23 samples from 8 cats). No sample was positive
by ELISA and negative by real-time PCR. However, 24
samples from 13 cats were positive by real-time PCR and
negative by p27 capture. Thus, real-time PCR had greaterats challenged with FeLV-61E-A
Tota
Latent Progressive
Provirus (++) Provirus (+++)
Antigen (+)Y() Antigen (+)
0 1 10
0 13 15
3 7 10
3 21
ection did not have detectable provirus at 8 weeks post-challenge. Both catsl
Fig. 2. Host–virus relationships defined using circulating p27 and viral DNA levels. FeLV-61E-A-infected cats classified as having experienced abortive infection
never had detectable p27 (A) or viral DNA (B) in blood. In cats with regressive infection, circulating p27was not detected but transient or persistent low viral DNA
levels were detectable in blood. Cats considered to have latent infection developed transient antigenemia and retained moderate viral DNA levels in blood. Cats
with progressive infectionwere persistently antigenemic and had persistent high circulating proviral burdens. Statistically significant differences ( P b 0.01) in p27
values were identified between progressive vs. abortive, progressive vs. regressive, and progressive vs. latent infection. Statistically significant differences ( P b
0.01) in proviral burdens were identified between abortive vs. regressive, abortive vs. latent, abortive vs. progressive, regressive vs. latent, and regressive vs.
progressive infection. Mean F SD are plotted. (A) The dotted line represents the threshold for positive results (z10% of the positive control).
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0.53, indicating a fair agreement between the two tests.
Pearson correlation coefficients were determined to
assess the linear relationship between circulating p27 levels
and PBMC viral DNA levels. After a Fisher’s r to z
transformation, P values were obtained. The correlation
between ELISA and real-time PCR became progressively
more concordant as infections became fully established as
indicated by the following trend in time periods: 2 weeks PC
r = 0.761, P b 0.01; 4 weeks PC r = 0.461, P b 0.05; 6
weeks PC r = 0.555, P b 0.01; and 8 weeks PC r = 0.640,
P b 0.01. After splitting the data by category of FeLV
infection, a more linear relationship between the assays
appeared: abortive infection r = not applicable (novariability in the data); regressive infection r = 0.831, P b
0.01; latent infection r = 0.896, P b 0.01; and progressive
infection r = 0.409, P b 0.01.
Long-term outcome and host–virus relationships in 13 of the
FeLV-challenged cats
Thirteen of the 35 cats studied above were available for
necropsy after survival periods of 2–3.5 years. This cohort
was comprised of five cats from the Vaccine A group, four
cats from the Vaccine B group, and four from the
unvaccinated Control group (Table 3). Sera were analyzed
for p27 capsid antigen via capture ELISA. PBMC, bone
marrow (BM), spleen (SP), and mesenteric lymph node
Table 3
Summary of study design
Group No. of
cats
Prime Boost Weeks of age
at challenge
No. of cats
necropsied
Weeks post-challenge
at necropsy
Vaccine A* 5a SQb SQ 22–23 5 90
5c SQ SQ 34–36 – –
Vaccine B** 5a INd IN 22–23 1 153
5a SQ IN 22–23 2 153
5a SQ – 22–23 1 153
Control*** 5a – – 22–23 2 153
5c – – 34–36 2 177
* = Fel-O-Vax Lv-K (Fort Dodge Animal Health). ** = Experimental whole inactivated FeLV-Sarma-A with MPL adjuvant. *** = No vaccine.
a Experiment 1.
b Subcutaneous administration of vaccine.
c Experiment 2.
d Intranasal administration of vaccine.
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quantitative real-time PCR. In addition, thymus, tonsil, and
retropharyngeal lymph node were available for the five cats
vaccinated with Vaccine A.
Abortive infection
Three cats that received Vaccine A and were categorized
as abortive infection (antigen negative/provirus negative)
remained antigen and provirus negative in blood after a 2-
year observation period (Fig. 3). Perhaps surprisingly, viral
DNA was not detectable in the BM, SP, or MLN of these
same animals. In addition, no viral DNA could be detected
in thymus, tonsil, or retropharyngeal lymph node (data not
shown). It would not be possible, therefore, to distinguishFig. 3. Early FeLV–host relationships were maintained for 2–3.5 years and provira
for necropsy after long-term survival periods. Sera were analyzed for antigenemia
DNA burden via quantitative real-time PCR. Three Vaccine A cats with abortiv
detectable viral DNA) remained p27 negative with undetectable viral DNA in PB
retropharyngeal lymph node) also were negative for viral DNA (data not shown).
retaining low viral DNA levels in PBMC, BM, SP, and MLN. The one unvacc
detectable viral DNA in PBMC, BM, SP, and MLN. The three Vaccine B cats an
positive with readily detectable viral DNA in PBMC, BM, SP, and MLN. Pearson c
vs. BM: r = 0.559, P N 0.05; PBMC vs. SP: r = 0.975, P b 0.01; and PBMC vs
infection as classified by the p27 and viral DNA assays during the first 8 weeks p
2Experimental group. VA = vaccine A, VB = vaccine B, C = unvaccinated control.
circulating nor tissue viral DNA was detected at euthanasia.these animals from those never exposed to FeLV on the
basis of antigen capture ELISA and viral DNA real-time
PCR assay results alone.
Regressive infection
Two cats that received Vaccine A and were classified as
regressive infection (antigen negative/low transient provi-
rus) (Table 2) also remained antigen- and provirus-negative
in blood nearly 2 years later. Similar to cats with abortive
infections, viral DNAwas not detected in BM, SP, or MLN,
nor was it detected in thymus, tonsil, and retropharyngeal
lymph node (data not shown). The one cat that received
Vaccine B and was classified as regressive infection (antigen
negative/persistent low proviral load) remained antigenl burdens in blood and tissues correlated. Thirteen of 35 cats were available
via p27 capture ELISA. PBMC, BM, SP, and MLN were analyzed for viral
e infection and two Vaccine A cats with regressive infection (transiently
MC, BM, SP, and MLN. Additional available tissues (thymus, tonsil, and
One Vaccine B cat with regressive infection remained p27-negative despite
inated control cat classified as latent infection became p27-positive with
d three unvaccinated control cats with progressive infection remained p27
orrelation coefficients and P values between PBMC and tissues were PBMC
. MLN: r = 0.823, P b 0.01. Means F SD are plotted. 1Category of FeLV
ost-challenge. A = abortive, R = regressive, L = latent, and P = progressive.
3A-VA represents results from 3 cats and R-VA from 2 cats, whereby neither
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detected at 8 weeks PC (6866 F 668 copies/106 PBMC)
were retained 3 years later (44 F 76 copies/106 PBMC) and
these levels were similar to those detected in BM, SP, and
MLN.
Latent infection
The one unvaccinated control cat classified as latent
infection (transient antigenemia/persistent moderate proviral
load) had become p27-positive 3 years later. Viral DNA
levels detected in PBMC of this animal were similar to BM,
SP, and MLN although PBMC levels (919 F 330 copies/106
PBMC) after 3 years were appreciably lower than those
detected at 8 weeks PC (94,184 F 4962 copies/106 PBMC).
Progressive infection
One cat that received Vaccine B and was considered to
have progressive infection also remained unchanged 3 years
later. The PBMC proviral load in this animal peaked at 4
weeks PC (518,096F 17,778 copies/106 PBMC), decreased
by 8 weeks PC (7330 F 133 copies/106 PBMC), and
remained relatively similar to the 8-week level 3 years later
(196 F 63 copies/106 PBMC). Proviral burdens in BM, SP,
and MLN were similar to blood levels. Two cats that
received Vaccine B and three unvaccinated control cats that
were classified as progressive infections (antigen positive/
persistent high proviral load) remained antigen-positive. The
relatively high PBMC viral DNA levels detected at 8 weeks
PC (639,174 F 593,815 copies/106 PBMC) were retained
3–3.5 years later (2,143,280 F 1,387,100 copies/106
PBMC) and these levels were similar to those detected in
BM, SP, and MLN.
Viral DNA levels in circulating cells correlated with
levels in tissues. Pearson correlation coefficients between
circulating and tissue viral DNA levels and the P values
after a Fisher’s r to z transformation were PBMC vs. BM:
r = 0.559, P N 0.05; PBMC vs. SP: r = 0.975, P b 0.01; and
PBMC vs. MLN: r = 0.823, P b 0.01.
In summary, it appeared in most instances the host–virus
relationship became established by 8 weeks and was
maintained for 2–3.5 years in blood and lymphoid tissues.Discussion
The primary purpose of this study was to develop and
validate a quantitative real-time DNA PCR assay to
examine FeLV-vaccinated and unvaccinated cats for viral
DNA sequences in circulating cells during the early phase
of FeLV infection and both circulating cells and tissue
during the late phase of FeLV infection. This assay was
based on an FeLV U3 LTR sequence and proved to be
reproducible, quantitative, sensitive, and specific for
exogenous FeLV. The greater sensitivity of real-time PCR
allowed detection of viral DNA in cats with undetectable
antigenemia. This finding is consistent with recent studiesof Flynn et al. (2002) and Hofmann-Lehmann et al. (2001).
The current real-time PCR assay, while similar to that
developed by Hofmann-Lehmann et al. (2001), is based on
FeLV-61E-A, the highly replication competent, non-acutely
pathogenic component of the FeLV–FAIDS complex
(Donahue et al., 1988; Hoover et al., 1987; Mullins et al.,
1986; Overbaugh et al., 1988). The U3 LTR region is
conserved among FeLV subgroup A viruses; thus, it is
probable that detection of cross-isolates will occur using
the present primer/probe set, although this issue was not
addressed in the present study. While unintegrated viral
DNA (UVD) is a characteristic of the FeLV-FAIDS strain,
this method cannot distinguish between integrated provirus
and UVD.
This would appear to be the first study assessing the
efficacy of an FeLV vaccine using real-time PCR. Nine of
the 10 cats that received Vaccine A (Fort Dodge Fel-O-Vax
Lv-K) were protected as indicated by the absence of
circulating FeLV p27. Moreover, in four of the nine pro-
tected vaccinates viral DNA was never detected in PBMC.
The remaining five protected cats had either transient low
(two cats) or persistent low (three cats) circulating viral
DNA levels within the first 8 weeks PC. Importantly, viral
DNAwas not detectable in PBMC or lymphoid tissues from
the five available animals, nearly 2 years after viral
challenge. Previous studies examining the efficacy of Fel-
O-Vax Lv-K reported preventable fractions of 86% and
100% (Hoover et al., 1995, 1996; Legendre et al., 1991).
Virus was not isolated from bone marrow cultures at 7 or 31
weeks post-challenge/exposure in these experiments (Hoo-
ver et al., 1995, 1996; Legendre et al., 1991). Results of the
present study bolster these previous findings, as do those of
Haffer et al. (1987) lending support to the tenet that
successful immunity to retroviral infection can be obtained
with immunoprophylaxis.
The greater sensitivity of real-time PCR allowed us to
suggest more detailed FeLV–host relationship categories,
which we designated as: abortive, regressive, latent, and
progressive. Although it is certainly plausible that these
categories of FeLV infection may be dynamic, especially the
intermediate categories, we found these host–virus relation-
ships became established by 8 weeks PC and were
maintained for years in the limited sample of FeLV-
challenged cats in the present study.
In the original FeLV–host relationship classification
scheme, animals with abortive, regressive, and latent
infection all would have been identified as regressive in-
fection due to the lack of persistent antigenemia. In 1980–
1982, it was subsequently discovered that at least some
antigen-negative cats, which experienced regressive infec-
tion, retain latent FeLV infection in bone marrow (Madewell
and Jarrett, 1983; Post and Warren, 1980; Rojko et al.,
1982). With the advent of PCR, this hypothesis was tested
using antigen-negative cats with suspected latent infections;
however, no viral DNA sequences were amplified from
blood or bone marrow cells (Herring et al., 2001; Jackson
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proposed that these antigen-negative cats did not harbor
latent virus in the sites examined. The results of the present
study suggest that neither scenario is absolute. Rather,
FeLV-exposed antigen-negative cats represent a spectrum
of host–virus relationships wherein some animals appear
to eliminate infected cells in circulation and tissues while
some maintain a low to moderate level of infected cells.
Reactivation is possible in the latter animals.
We hypothesize that cats with abortive infection pro-
duced effective early host immune responses, which
abrogate viral replication and eliminate FeLV-infected cells.
This is inconsistent with the hypothesis that all FeLV-
exposed antigen-negative cats harbor a reservoir of infected
cells in some hemolymphatic tissue. It remains possible,
though not probable in our view, that such animals harbor
sequestered FeLV in tissues not examined. It is also possible
that the real-time PCR assay is not sufficiently sensitive to
detect extraordinarily low proviral levels, as has been
proposed to occur in people who are repeatedly exposed
to human immunodeficiency virus yet remain seronegative
(Zhu et al., 2003). Our present observations bolster the
contention that some individuals can resist retroviral
infection without conventional evidence of infection.
We propose that cats with regressive infection success-
fully contain viral replication despite retaining a low level of
FeLV-infected cells in circulation and tissues. Some of these
animals even eliminate these infected cells and go on to
resemble cats with abortive infections. This supports the
hypothesis that some FeLV-exposed antigen-negative cats
can maintain populations of nonproductive, infected cells.
Our results also demonstrate that these cats harbor viral
DNA in circulation and lymphoid tissues in addition to bone
marrow. While reactivation of regressive infection may be
possible, this was not detected in the present study. Overall,
the present study suggests a more likely outcome of
eventual elimination or extinction of infected cells.
We propose in cats classified as latent infection that
delayed containment of viral replication occurs resulting in
a moderate proviral residuum. As a corollary, if host
immune containment wanes, viral reactivation becomes
more likely. This is consistent with the tenet that some
FeLV-exposed antigen-negative cats can maintain cell
populations harboring replication-competent latent FeLV
capable of reactivation.
We assume that residual viral DNA detected by real-time
PCR could represent intact provirus or replication-defective
sequences. Previous studies have reported that nonviremic
cats from which FeLV was isolated from cultured BM cells
did not horizontally transmit FeLV (Madewell and Jarrett,
1983; Pacitti and Jarrett, 1985; Pedersen et al., 1984).
However, vertical transmission to offspring from similar
animals also has been reported (Pacitti et al., 1986; Pedersen
et al., 1984). Additional studies are needed to assess the
state and fate of viral DNA in latently infected cats. Such
issues are pertinent to use of FeLV antigen-negative cats forblood donation, tissue transplants, and adoptions, as well as
to the use of therapeutic immunosuppressive drugs in
antigen-negative cats (Coronado et al., 2000; Gregory
et al., 1991; Nemzek et al., 1994, 1996).
That effective containment of human immunodeficiency
virus may be possible is inferred by long-term nonprog-
ression in HIV-infected individuals and apparent resistance
to infection in highly HIV-exposed seronegative individuals.
Genetic, virological, and immunological factors all likely
play a role in HIV containment (Cohen et al., 1997; Haynes
et al., 1996; Levy, 1993; Rowland-Jones and McMichael,
1995). Animal models present unique opportunities to
prospectively examine the initial events in immunopatho-
genesis. Further examination of the early immune responses
that determine effective vs. ineffective containment of FeLV
infection and better characterization of the latent viral state
would provide valuable insights into retroviral pathogenesis
and resistance overall.Materials and methods
Study design
This is a retrospective analysis. Samples were utilized
from two previous vaccine experiments. Experiment 1
consisted of five groups: group 1 received Vaccine A, groups
2, 3, and 4 all received Vaccine B but each by different routes
of administration, and group 5 served as the Control as these
cats did not receive any vaccination. Using repeated-
measures ANOVA, no statistically significant differences
were detected between the three groups that received Vaccine
B by different routes of administration (P = 0.47, power =
0.15). Consequently, results from the three groups that
received Vaccine B were combined. Experiment 2 consisted
of two groups: group 1 received Vaccine A and group 2
served as the Control as these cats did not receive any
vaccination. Again, no statistically significant differences
were detected between the Vaccine A groups from Experi-
ment 1 and 2 (P = 0.16 power = 0.27) or between the Control
groups from Experiment 1 and 2 (P = 0.53, power = 0.09).
Thus, results from the Vaccine A groups from Experiment 1
and Experiment 2 were combined and results from the
Control groups from Experiment 1 and Experiment 2 were
combined. In summary, this study presents the results from a
combined total of 3 groups: Vaccine A, Vaccine B, and
Control (Table 3).
Experimental animals
Thirty-five specific-pathogen-free (SPF) cats were
obtained from Cedar River Laboratories (Mason City, IA)
and randomly divided into seven groups, each group
consisting of five cats (Table 3). Each group was individ-
ually housed at Laboratory Animal Resources at Colorado
State University (Fort Collins, CO) in accordance with the
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Vaccination, virus challenge, and all sample collections
were performed on cats anesthetized with a subcutaneous
administration of ketamine hydrochloride (22mg/kg) and
acepromazine maleate (0.1mg/kg).
Vaccination
Ten cats were administered Vaccine A, the commercial
FeLV vaccine Fel-O-Vax Lv-K (Fort Dodge Animal Health,
Overland Park, KS) (Hoover et al., 1995, 1996), according
to the manufacturer’s specifications (Table 3). Five cats
received the subcutaneous priming vaccination at 15–16
weeks of age and a subcutaneous boosting vaccination at
19–20 weeks of age. The other five cats received the prime
at 25–27 weeks of age and the boost at 31–33 weeks of age.
Fifteen cats were administered Vaccine B, an experimental
whole inactivated FeLV-Sarma-A with monophosphoryl
lipid A adjuvant (MPL) (Corixa Corp., Seattle, WA), by
different routes of administration. All 15 cats received the
priming vaccination at 15–16 weeks of age and a boosting
vaccination at 19–20 week of age. Five cats received an
intranasal prime and boost, five cats received a subcuta-
neous prime and an intranasal boost, and five cats received a
subcutaneous prime and no boost. Ten cats did not receive
any vaccinations and served as the Controls.
Virus challenge
All cats were challenged oronasally with 1 mL of 104
TCID/mL FeLV-61E-A via dropwise instillation of 0.25 mL
in each nostril and 0.5 mL in the mouth. This subgroup A
virus strain is the highly replication competent, non-acutely
pathogenic component of the FeLV–FAIDS complex
(Donahue et al., 1988; Hoover et al., 1987; Mullins et al.,
1986; Overbaugh et al., 1988). The cell-free infectious virus
inoculum was prepared as supernatant from Crandell feline
kidney (CrFK) cell cultures and determined to be equivalent
to 1 CID100 (100% cat infective dose). The vaccinates were
challenged 3 weeks after receiving their boosting immuni-
zation; either 22–23 or 34–36 weeks of age (Table 3). Five
control cats were challenged at 22–23 weeks of age and the
other five at 34–36 weeks of age. All cats were observed
daily for signs of illness after virus inoculation.
Sample collection and processing
Blood samples were collected at challenge and every 2
weeks thereafter through 8 weeks post-challenge (PC). Sera
were stored at 20 8C until analysis for FeLV p27 capsid
antigen by capture ELISA. Peripheral blood mononuclear
cells (PBMC) were isolated from blood by ficoll-hypaque
(Histopaque-1077; Sigma Diagnostics, St. Louis, MO)
density gradient centrifugation, separated into 1  106
PBMC/mL aliquots, and stored at 80 8C until analysis by
FeLV quantitative real-time PCR. DNA was extracted fromPBMC using a QIAamp DNA blood mini kit (Qiagen, Inc.,
Valencia, CA), eluted in 100 AL of elution buffer, and DNA
concentrations determined spectrophotometrically.
Thirteen of the 35 cats were available for necropsy after
long-term survival periods. Five cats from the Vaccine A
group were necropsied at 90 weeks PC, 4 cats from the
Vaccine B group and 2 from the unvaccinated Control group
were necropsied at 153 weeks PC, and 2 cats from the
unvaccinated Control group were necropsied at 177 weeks
PC (Table 3). Blood was collected and processed as above.
The thymus, tonsil, retropharyngeal lymph nodes, bone
marrow (BM), spleen (SP), and mesenteric lymph nodes
(MLN) were collected from the five Vaccine A cats. BM,
SP, and MLN were collected from the four Vaccine B and
four unvaccinated control cats. Tissues were stored at 80
8C until analysis by FeLV quantitative real-time PCR. DNA
was extracted and RNA digested from tissues using a
QIAampR DNA mini kit and RNase A (Qiagen, Inc.),
respectively, eluted in 100 AL of elution buffer, and DNA
concentrations determined spectrophotometrically.
Detection of circulating p27 capsid antigen by capture
ELISA
FeLV p27 capsid antigen was detected in serum by capture
ELISA using the monoclonal antibodies (mAbs) anti-p27 A2
and G3 (Lutz et al., 1983) (kindly provided by Niels C.
Pedersen; University of California, Davis, CA) as previously
described (Zeidner et al., 1990) with minor adaptations.
Briefly, 0.5 Ag/well of the primary mAb, G3, was used to coat
a 96-well plate, 50 AL of control or sample sera was added in
duplicate to plate wells, and 50 AL of the secondary
horseradish peroxidase-conjugated mAb, A2 at 1:250, was
added and incubated for 45 min. The plates were then rinsed
and 100 AL/well TMB peroxidase substrate:peroxidase
solution B (H2O2) (Kirkegaard and Perry Laboratories,
Gaithersburg, MD) was added for color development. After
a 15-min incubation, reactions were stopped with 50 AL/well
2N H2SO4 and optical density measurements were taken at
450 nm. Background readings, using FeLV-naRve SPF cat
serum, were subtracted from each well. Sample well reactions
were considered positive if an absorbance value of 10% or
more of the positive control (persistent antigenemic FeLV-
infected cat serum) was obtained.
Detection and quantification of circulating and tissue FeLV
viral DNA by quantitative real-time PCR
Using Primer Express software (Applied Biosystems,
Foster City, CA), we designed a primer/probe set within the
U3 region of the FeLV-61E-A long terminal repeat (LTR)
(GenBank accession number M18247) (Donahue et al.,
1988), thereby amplifying the exogenous but not endoge-
nous FeLV sequences (Berry et al., 1988; Casey et al.,
1981). The forward, 5V AGTTCGACCTTCCGCCTCAT 3V
(20 bases; nt 241–260), and reverse, 5V AGAAAGCQ
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sequences amplified a 68-bp fragment. The corresponding
probe sequence, 5V TAAACTAACCAATCCCCATGQ
CCTCTCGC 3V (28 bases; nt 262–289), was labeled with
the reporter dye, FAM (6-carboxyfluorescein), at the 5V end
and the quencher dye, TAMRA (6-carboxytetramethyl-
rhodamine; Applied Biosystems) or BHQ-1 (Black Hole
Quencher-1; Biosource International, Inc., Camarillo, CA),
at the 3V end. Both probes were blocked at the 3V end to
prevent extension. The two probes produced similar results.
The 25-AL reaction consisted of 400 nM of each primer,
80 nM of fluorogenic probe, 12.5 AL of TaqMan Universal
PCR Master Mix (Applied Biosystems), 3.5 AL of PCR-
grade H2O, and 5 AL of sample or plasmid standard DNA.
The master mix was supplied at a 2 concentration and
contained AmpliTaq Gold DNA Polymerase, AmpErase
uracil N-glycosylase (UNG), dNTPs with dUTP, and
optimized buffer components. Reactions were performed
in triplicate using an iCycler iQ real-time PCR detection
system (Bio-Rad Laboratories, Inc., Hercules, CA). Every
reaction plate contained a template control (no DNA, PCR-
grade H2O only) and a negative control (FeLV-naRve, SPF
cat DNA). Thermal cycling conditions were 2 min at 50 8C
to allow enzymatic activity of UNG, 10 min at 95 8C to
reduce UNG activity, to activate AmpliTaq Gold DNA
Polymerase, and to denature the template DNA, followed by
40 cycles of 15 s at 95 8C for denaturation and 60 s at 60 8C
for annealing/extension.
The plasmid p61E-FeLV, an EcoRI fragment containing
the full-length FeLV-61E-A provirus subcloned into pUC18
(Donahue et al., 1988; Overbaugh et al., 1988), was used as
the standard for PCR quantification. The plasmid was
provided as ampicillin-resistant transformed E. coli JM109
cells through the AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH, from Dr. James
Mullins. The transformed E. coli cells were grown on LB
media containing 50 Ag/mL ampicillin. Plasmid DNA was
isolated from the bacterial cells using the QIAfilter plasmid
midi kit (Qiagen, Inc.), linearized with EcoRI, and the full-
length FeLV-61E fragment was confirmed by agarose gel
electrophoresis with ethidium bromide staining. The line-
arized plasmid standard copy number was calculated from
optical density measurements at 260 nm. A 10-fold dilution
series of the plasmid standard template DNA was made in
1 TE buffer with 40 ng/AL salmon testes DNA (Sigma
Chemical Co., St. Louis, MO) as a carrier. Quantification of
the sample amplicon was achieved by comparing the
threshold cycle (CT) value of the sample DNA with the
standard curve of the co-amplified standard template DNA.
Cell numbers were calculated by assuming 6 pg DNA/cell.
Analytical specificity and sensitivity of FeLV quantitative
real-time PCR
Following agarose gel electrophoresis confirmation with
GelStar (BioWhittaker Molecular Applications, Rockland,ME) staining, the 68-bp PCR products from two separate
reactions were sequenced to verify analytical specificity.
The TOPO TA Cloning Kit (with pCR 2.1-TOPO vector)
(Invitrogen Corp., Carlsbad, CA) was used for cloning the
amplicons prior to sequencing. Briefly, the PCR products
were directly ligated into the linearized pCR 2.1-TOPO
vector (Invitrogen Corp.), the constructs were transformed
into One Shot TOP 10 chemically competent E. coli cells
(Invitrogen Corp.), and the cells grown on LB media with
50 Ag/mL ampicillin using blue/white screening. Plasmid
DNA was isolated from the bacterial cells using the
QIAfilter plasmid midi kit (Qiagen, Inc.), linearized with
EcoRI, and the plasmid insert confirmed by agarose gel
electrophoresis with GelStar (BioWhittaker Molecular
Applications) staining. Two cloned inserts were sequenced
by Davis Sequencing LLC (Davis, CA). The sequences of
the PCR products were then aligned with FeLV-61E-A using
BLAST (Altschul et al., 1990; Wheeler et al., 2003) on the
National Center for Biotechnology Information website.
End-point dilution experiments of the p61E-FeLV
plasmid standard were performed to assess analytical
sensitivity. A dilution series of 500, 100, 50, 10, 5, 1, 0.5,
and 0.1 copies of the plasmid standard, each in triplicate,
was tested.
Amplification efficiency and reproducibility of FeLV
quantitative real-time PCR
To assess amplification efficiencies, serial dilutions
(1:10, 1:100, 1:1000, and 1:10000) of PBMC DNA from
an experimentally FeLV-61E-A-infected cat and of the
p61E-FeLV plasmid standard were amplified in triplicate
and the difference in the slopes (Ds) of the regression lines
(CT vs. dilution) was evaluated.
To assess assay reproducibility, dilutions of the p61E-
FeLV plasmid standard (50000, 5000, and 500 copies)
and of DNA from an experimentally FeLV-61E-A-infected
cat (100%, 1:100, and 1:1000) were evaluated for within-
run and between-run precision. Each dilution was run 10
times within the same reaction plate and between 10
different reaction plates to test the within-run and
between-run precision, respectively. The coefficients of
variations (CV) of the threshold cycles (CT) were calcu-
lated: CV (CT).
Statistics
Statistically significant differences in p27 and viral DNA
levels (log transformed) between the experimental groups
and between the FeLV–host categories were determined
using repeated-measure analysis of variance (ANOVA) with
the Tukey–Kramer post hoc test. A statistically significant
difference between groups was considered to have occurred
when a P value was b0.05. The kappa statistic was
calculated to assess the level of agreement, beyond that
which might be expected due to chance, between the p27
A.N. Torres et al. / Virology 332 (2005) 272–283282capture ELISA and the real-time PCR assay. Pearson
correlation coefficients were determined to assess the linear
relationship between circulating p27 levels vs. PBMC viral
DNA levels and between circulating vs. tissue viral DNA
levels. After a Fisher’s r to z transformation, P values were
obtained. Again, a statistically significant difference
between groups was considered to have occurred when
the P value was b0.05. Repeated-measures ANOVA, the
Tukey–Kramer post hoc test, and the Pearson correlation
coefficient were performed using StatView version 5.0.1 for
Macintosh, copyright 1999 (Abacus Concepts, Inc., Berke-
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